Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer-Reference-Cited by-同舟云学术

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

Published:2016-03 Issue:7 Volume:114 Page:737-743
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Stein Stacey M,James Edward S,Deng Yanhong,Cong Xiangyu,Kortmansky Jeremy S,Li Jia,Staugaard Carol,Indukala Doddamane,Boustani Ann Marie,Patel Vatsal,Cha Charles H,Salem Ronald R,Chang Bryan,Hochster Howard S,Lacy Jill

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201645.pdf

Reference23 articles.

1. Callery M, Chang K, Fishman E, Talamonti MS, William Traverso L, Linehan DC (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert Consensus Statement. Ann Surg Oncol 16 (7): 1727–1733.

2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19): 1817–1825.

3. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 23 (6): 1228–1236.

4. Day F, Link E, Ngan S, Leong T, Moodie K, Lynch C, Michael M, Winton Ed, Hogg A, Hicks RJ, Heriot A (2011) FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer 105 (4): 498–504.

5. Faris J, Blaszkowsky L, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS (2013) FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 18 (5): 543–548.

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma;BMC Medicine;2024-09-04

2. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma;The Oncologist;2024-09-03

3. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer;JAMA Oncology;2024-08-01

4. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer;Journal of Hepato-Biliary-Pancreatic Sciences;2024-07-21

5. Update on management of pancreatic cancer: a literature review;Chinese Clinical Oncology;2024-06